Shares of Syros Pharmaceuticals Inc (NASDAQ:SYRS) were up 11% during mid-day trading on Tuesday . The stock traded as high as $10.39 and last traded at $9.99, with a volume of 125,369 shares changing hands. The stock had previously closed at $9.00.

A number of equities analysts have weighed in on SYRS shares. Piper Jaffray Cos. started coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 25th. They issued an “overweight” rating and a $20.00 price objective for the company. JMP Securities started coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 25th. They issued an “outperform” rating and a $22.00 price objective for the company. HC Wainwright started coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 18th. They issued a “neutral” rating and a $10.00 price objective for the company. Wedbush started coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 25th. They issued an “outperform” rating and a $18.00 price objective for the company. Finally, Cowen and Company started coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 25th. They issued an “outperform” rating for the company. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $17.50.

The company’s market cap is $118.97 million. The company has a 50-day moving average of $0.00 and a 200 day moving average of $0.00.

In related news, major shareholder Redmile Group, Llc bought 432,746 shares of the firm’s stock in a transaction on Wednesday, July 6th. The stock was bought at an average price of $12.50 per share, with a total value of $5,409,325.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Robert Nelsen bought 400,000 shares of the firm’s stock in a transaction on Wednesday, July 6th. The shares were bought at an average cost of $12.50 per share, with a total value of $5,000,000.00. The disclosure for this purchase can be found here.

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.